Fig. 5From: Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New ZealandSurvival outcomes from EGFR-TKI treatment in a group of untested NSCLC patients (n = 129) by estimated EGFR mutation probability (pr < 0.2, 0.2–0.6, and > 0.6)Back to article page